C2i Genomics

C2i Genomics is headquartered in New York and operates as a subsidiary of Veracyte, focusing on the enhancement of cancer treatment and monitoring. The company has developed a whole-genome cancer treatment intelligence platform that offers a blood test capable of detecting minute amounts of residual cancer. This test is crucial for monitoring treatment effectiveness, disease progression, and potential recurrence. C2i Genomics utilizes a Software as a Service (SaaS) model to provide a global cancer tumor burden monitoring platform. This platform is integrated with thousands of genome sequencers worldwide, facilitating accessible and real-time cancer monitoring. The company’s operations also include a research and development center located in Israel and a sequencing laboratory in Watertown, Massachusetts. To date, C2i Genomics has processed over 1,000 samples using its innovative platform.